Treatment-Resistant Depression
Midwest CEPAC
May 23, 2019
9am- 5pm CT
Hyatt Regency O’Hare
9300 Bryn Mawr Avenue
Rosemont, IL 60018
The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.
Key Dates
Associated Materials
10/10/2018 – 10/30/2018
10/31/2018
10/31/2018
10/31/2018 – 11/20/2018
11/29/2018
01/14/2019
02/04/2019
03/21/2019
03/21/2019
03/21/2019 – 04/17/2019
05/09/2019
05/09/2019
05/09/2019
05/23/2019
05/23/2019
06/20/2019
06/20/2019
